249 related articles for article (PubMed ID: 33924134)
1. Implementation of Precision Oncology for Patients with Metastatic Breast Cancer in an Interdisciplinary MTB Setting.
Sultova E; Westphalen CB; Jung A; Kumbrink J; Kirchner T; Mayr D; Rudelius M; Ormanns S; Heinemann V; Metzeler KH; Greif PA; Hester A; Mahner S; Harbeck N; Wuerstlein R
Diagnostics (Basel); 2021 Apr; 11(4):. PubMed ID: 33924134
[TBL] [Abstract][Full Text] [Related]
2. NGS-guided precision oncology in metastatic breast and gynecological cancer: first experiences at the CCC Munich LMU.
Sultova E; Westphalen CB; Jung A; Kumbrink J; Kirchner T; Mayr D; Rudelius M; Ormanns S; Heinemann V; Metzeler KH; Greif PA; Burges A; Trillsch F; Mahner S; Harbeck N; Wuerstlein R
Arch Gynecol Obstet; 2021 May; 303(5):1331-1345. PubMed ID: 33277683
[TBL] [Abstract][Full Text] [Related]
3. NGS-Guided Precision Oncology in Breast Cancer and Gynecological Tumors-A Retrospective Molecular Tumor Board Analysis.
Gremke N; Rodepeter FR; Teply-Szymanski J; Griewing S; Boekhoff J; Stroh A; Tarawneh TS; Riera-Knorrenschild J; Balser C; Hattesohl A; Middeke M; Ross P; Litmeyer AS; Romey M; Stiewe T; Wündisch T; Neubauer A; Denkert C; Wagner U; Mack EKM
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672643
[No Abstract] [Full Text] [Related]
4. HOPE (SOLTI-1903) breast cancer study: real-world, patient-centric, clinical practice study to assess the impact of genomic data on next treatment decision-choice in patients with locally advanced or metastatic breast cancer.
Olivera-Salguero R; Seguí E; Cejalvo JM; Oliveira M; Tolosa P; Vidal M; Malumbres M; Gavilá J; Saura C; Pernas S; López R; Margelí M; Balmaña J; Muñoz M; Blancas I; Boni V; Ciruelos E; Galve E; Perelló A; Sánchez-Bayona R; de la Cruz S; de la Hoya M; Galván P; Sanfeliu E; Gonzalez-Farre B; Sirenko V; Blanch-Torras A; Canes J; Masanas H; Olmos R; Forns M; Prat A; Casas A; Pascual T
Front Oncol; 2023; 13():1151496. PubMed ID: 37188177
[TBL] [Abstract][Full Text] [Related]
5. Establishment of a Molecular Tumor Board (MTB) and Uptake of Recommendations in a Community Setting.
VanderWalde A; Grothey A; Vaena D; Vidal G; ElNaggar A; Bufalino G; Schwartzberg L
J Pers Med; 2020 Nov; 10(4):. PubMed ID: 33260805
[TBL] [Abstract][Full Text] [Related]
6. Role of the Molecular Tumor Board for the Personalized Treatment of Patients with Metastatic Breast Cancer: A Focus on the State of the Art in Italy.
Irelli A; Chiatamone Ranieri S; Di Giacomo D; Malatesta S; Patruno LV; Tessitore A; Alesse E; Cannita K
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980613
[TBL] [Abstract][Full Text] [Related]
7. Implementing precision oncology for sarcoma patients: the CCC
Berclaz LM; Burkhard-Meier A; Lange P; Di Gioia D; Schmidt M; Knösel T; Klauschen F; von Bergwelt-Baildon M; Heinemann V; Greif PA; Westphalen CB; Heinrich K; Lindner LH
J Cancer Res Clin Oncol; 2023 Nov; 149(15):13973-13983. PubMed ID: 37542550
[TBL] [Abstract][Full Text] [Related]
8. Molecular profiling of male breast cancer by multigene panel testing: Implications for precision oncology.
Valentini V; Silvestri V; Bucalo A; Conti G; Karimi M; Di Francesco L; Pomati G; Mezi S; Cerbelli B; Pignataro MG; Nicolussi A; Coppa A; D'Amati G; Giannini G; Ottini L
Front Oncol; 2022; 12():1092201. PubMed ID: 36686738
[TBL] [Abstract][Full Text] [Related]
9. Implementation and utilization of the molecular tumor board to guide precision medicine.
Harada S; Arend R; Dai Q; Levesque JA; Winokur TS; Guo R; Heslin MJ; Nabell L; Nabors LB; Limdi NA; Roth KA; Partridge EE; Siegal GP; Yang ES
Oncotarget; 2017 Aug; 8(34):57845-57854. PubMed ID: 28915716
[TBL] [Abstract][Full Text] [Related]
10. Molecular Tumour Board (MTB): From Standard Therapy to Precision Medicine.
Ballatore Z; Bozzi F; Cardea S; Savino FD; Migliore A; Tarantino V; Chiodi N; Ambrosini E; Bianchi F; Goteri G; Filosa A; Barbisan F; Bartoli E; Papa R; Berardi R
J Clin Med; 2023 Oct; 12(20):. PubMed ID: 37892804
[No Abstract] [Full Text] [Related]
11. Combined Focused Next-Generation Sequencing Assays to Guide Precision Oncology in Solid Tumors: A Retrospective Analysis from an Institutional Molecular Tumor Board.
Tarawneh TS; Rodepeter FR; Teply-Szymanski J; Ross P; Koch V; Thölken C; Schäfer JA; Gremke N; Mack HID; Gold J; Riera-Knorrenschild J; Wilhelm C; Rinke A; Middeke M; Klemmer A; Romey M; Hattesohl A; Jesinghaus M; Görg C; Figiel J; Chung HR; Wündisch T; Neubauer A; Denkert C; Mack EKM
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139590
[TBL] [Abstract][Full Text] [Related]
12. Framework for Implementing and Tracking a Molecular Tumor Board at a National Cancer Institute-Designated Comprehensive Cancer Center.
Jain NM; Schmalz L; Cann C; Holland A; Osterman T; Lang K; Wiesner GL; Pal T; Lovly C; Stricker T; Micheel C; Balko JM; Johnson DB; Park BH; Iams W
Oncologist; 2021 Nov; 26(11):e1962-e1970. PubMed ID: 34390291
[TBL] [Abstract][Full Text] [Related]
13. Transitioning the Molecular Tumor Board from Proof of Concept to Clinical Routine: A German Single-Center Analysis.
Hoefflin R; Lazarou A; Hess ME; Reiser M; Wehrle J; Metzger P; Frey AV; Becker H; Aumann K; Berner K; Boeker M; Buettner N; Dierks C; Duque-Afonso J; Eisenblaetter M; Erbes T; Fritsch R; Ge IX; Geißler AL; Grabbert M; Heeg S; Heiland DH; Hettmer S; Kayser G; Keller A; Kleiber A; Kutilina A; Mehmed L; Meiss F; Poxleitner P; Rawluk J; Ruf J; Schäfer H; Scherer F; Shoumariyeh K; Tzschach A; Peters C; Brummer T; Werner M; Duyster J; Lassmann S; Miething C; Boerries M; Illert AL; von Bubnoff N
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33800365
[TBL] [Abstract][Full Text] [Related]
14. CATCH: A Prospective Precision Oncology Trial in Metastatic Breast Cancer.
Hlevnjak M; Schulze M; Elgaafary S; Fremd C; Michel L; Beck K; Pfütze K; Richter D; Wolf S; Horak P; Kreutzfeldt S; Pixberg C; Hutter B; Ishaque N; Hirsch S; Gieldon L; Stenzinger A; Springfeld C; Smetanay K; Seitz J; Mavratzas A; Brors B; Kirsten R; Schuetz F; Fröhling S; Sinn HP; Jäger D; Thewes V; Zapatka M; Lichter P; Schneeweiss A
JCO Precis Oncol; 2021; 5():. PubMed ID: 34036222
[TBL] [Abstract][Full Text] [Related]
15. Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical Center.
Tafe LJ; Gorlov IP; de Abreu FB; Lefferts JA; Liu X; Pettus JR; Marotti JD; Bloch KJ; Memoli VA; Suriawinata AA; Dragnev KH; Fadul CE; Schwartz GN; Morgan CR; Holderness BM; Peterson JD; Tsongalis GJ; Miller TW; Chamberlin MD
Oncologist; 2015 Sep; 20(9):1011-8. PubMed ID: 26205736
[TBL] [Abstract][Full Text] [Related]
16. Multidisciplinary molecular tumour board: a tool to improve clinical practice and selection accrual for clinical trials in patients with cancer.
Rolfo C; Manca P; Salgado R; Van Dam P; Dendooven A; Ferri Gandia J; Rutten A; Lybaert W; Vermeij J; Gevaert T; Weyn C; Lefebure A; Metsu S; Van Laere S; Peeters M; Pauwels P; Machado Coelho A
ESMO Open; 2018; 3(5):e000398. PubMed ID: 30094075
[TBL] [Abstract][Full Text] [Related]
17. Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.
Zivanovic Bujak A; Weng CF; Silva MJ; Yeung M; Lo L; Ftouni S; Litchfield C; Ko YA; Kuykhoven K; Van Geelen C; Chandrashekar S; Dawson MA; Loi S; Wong SQ; Dawson SJ
PLoS Med; 2020 Oct; 17(10):e1003363. PubMed ID: 33001984
[TBL] [Abstract][Full Text] [Related]
18. Molecular profiling of metastatic breast cancer and target-based therapeutic matching in an Asian tertiary phase I oncology unit.
Walsh RJ; Ong R; Cheo SW; Low PQJ; Jayagopal A; Lee M; Ngoi N; Ow SG; Wong ALA; Lim SE; Lim YW; Heong V; Sundar R; Soo RA; Chee CE; Yong WP; Goh BC; Lee SC; Tan DSP; Lim JSJ
Front Oncol; 2024; 14():1342346. PubMed ID: 38812774
[TBL] [Abstract][Full Text] [Related]
19. Next-Generation Sequencing-Directed Therapy in Patients with Metastatic Breast Cancer in Routine Clinical Practice.
Bruzas S; Kuemmel S; Harrach H; Breit E; Ataseven B; Traut A; Rüland A; Kostara A; Chiari O; Dittmer-Grabowski C; Reinisch M
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572791
[TBL] [Abstract][Full Text] [Related]
20. Primary Results of Patients with Genitourinary Malignancies Presented at a Molecular Tumor Board.
Michaelis J; Himmelsbach R; Metzger P; Lassmann S; Börries M; Werner M; Miething C; Höfflin R; Illert AL; Duyster J; Becker H; Sigle A; Gratzke C; Grabbert M
Urol Int; 2024 Apr; ():1-9. PubMed ID: 38626735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
